Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to initially evaluate the optimal dose, efficacy, and safety of vitamin D3 for reducing recurrence of recurrent urinary tract infections (rUTIs).


Clinical Trial Description

Urinary tract infection (UTI) is a multiple disease that ranks second only to respiratory infections in infectious diseases and is one of the most common infectious diseases among adults. After the first urinary tract infection, the probability of recurrence within half a year and within one year was as high as 24% and 70%, respectively. Urinary tract infection itself has the characteristics of easy recurrence, which is closely related to the abuse of antibiotics, the generation of bacterial resistance, and the decline of local immune function of mucosa. In the urinary tract, the antibacterial peptide Cathelicidin is mainly located in the proximal tubules of the kidney and the epithelial cells of the renal pelvis and ureter. LL37 is the only antibacterial peptide present in the human body of the Cathelicidin family, which can be regarded as a natural antibiotic produced by the body. Antibacterial peptides have a broad-spectrum antibacterial effect and can exert antibacterial effects against both Gram-positive and Gram-negative bacteria. Vitamin D intake increases the activity of endogenous antimicrobial peptides. Preclinical cell test of Zensun Sci. & Tech. Co., Ltd. confirmed the induction of LL37 in urethral epithelial cells by vitamin D and its broad-spectrum antibacterial effect. Animal experiments also showed the therapeutic effect of LL37 on UTI. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04859621
Study type Interventional
Source Zensun Sci. & Tech. Co., Ltd.
Contact Debing Jiang
Phone 86-21-50802627
Email dbjiang@zensun.com
Status Recruiting
Phase Phase 2
Start date May 8, 2021
Completion date July 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT02357758 - Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Phase 4
Completed NCT04306731 - Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections. N/A
Recruiting NCT05553652 - The Effect of ASTARTEā„¢ on Recurrent Urinary Tract Infection N/A
Completed NCT01958073 - Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women Phase 4
Recruiting NCT05652374 - Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study Phase 4
Recruiting NCT06124820 - RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections N/A
Recruiting NCT04807894 - Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo Phase 4
Enrolling by invitation NCT04077580 - The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI Phase 4
Terminated NCT03143920 - Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder Early Phase 1
Terminated NCT04831840 - Recurrent Urinary Tract Infections and the Microbiome
Withdrawn NCT03854396 - Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women Phase 3
Completed NCT02705495 - Acupuncture for Prevention of Recurrent Urinary Tract Infections. N/A
Active, not recruiting NCT05537519 - Phage Therapy for the Treatment of Urinary Tract Infection Phase 1/Phase 2
Recruiting NCT06035601 - EHR-integrated rUTI Texting Platform N/A
Not yet recruiting NCT04285320 - Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections Phase 4
Recruiting NCT03142295 - Controlled Human Urine Transfusion for UTI N/A
Recruiting NCT05895578 - Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection. N/A
Completed NCT00214045 - Rigid Versus Flexible Cystoscopy in Women N/A
Enrolling by invitation NCT05551949 - Preventing Recurrent UTI With Vaginal Estrogen Phase 4
Recruiting NCT05472779 - Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections Phase 2